Evidence map›Paper›PMID 39355355›Full record

ArticleNagoya journal of medical science2024

Thyroid autoantibodies at baseline predict longer survival in non-small cell lung cancer patients treated with anti-programmed cell death-1 blockade: a prospective study.

Takayuki Okuji, Shintaro Iwama, Tomoko Kobayashi, Yoshinori Yasuda, Masaaki Ito, Ayana Yamagami, Masahiko Ando, Tetsunari Hase, Hirofumi Shibata, Takahiro Hatta and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nagoya journal of medical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Takayuki OkujiDepartment of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Shintaro IwamaDepartment of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Tomoko KobayashiDepartment of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yoshinori YasudaDepartment of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Masaaki ItoDepartment of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Ayana YamagamiDepartment of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Masahiko AndoCenter for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan.
Tetsunari HaseDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hirofumi ShibataDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Takahiro HattaDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Xin ZhouDepartment of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Takeshi OnoueDepartment of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yohei KawaguchiDepartment of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Takashi MiyataDepartment of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Mariko SugiyamaDepartment of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Daisuke HagiwaraDepartment of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hidetaka SugaDepartment of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Ryoichi BannoDepartment of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yuichi AndoDepartment of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.
Naozumi HashimotoDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hiroshi ArimaDepartment of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The presence of anti-thyroid antibodies (ATAs) is a biomarker for the development of thyroid dysfunction induced by anti-programmed cell death-1 antibodies (PD-1-Abs). While patients with thyroid dysfunction reportedly showed better overall survival (OS), it remains unknown if ATAs at baseline can predict OS. Therefore, in this study, we examined the association of ATAs at baseline with OS in non-small cell lung cancer (NSCLC) patients with different levels of programmed cell death-1 ligand 1 (PD-L1) positivity associated with PD-1-Ab treatment efficacy. A total of 81 NSCLC patients treated with PD-1-Abs were evaluated for ATAs at baseline and prospectively for OS. Among the 81 patients, 49 and 32 patients had ≥50% (group A) and <50% (group B) PD-L1 positivity, respectively. Median OS did not differ significantly between patients with (n = 13) and without (n = 36) ATAs at baseline in group A. In contrast, median OS was significantly longer in patients with (n = 10) versus without (n = 22) ATAs at baseline in group B (not reached vs 378 days, respectively; 95% CI, 182 to 574 days,

Indexed as

AutoantibodiesCarcinoma, Non-Small-Cell LungLung NeoplasmsAgedAged, 80 and overB7-H1 AntigenFemaleHumansImmune Checkpoint InhibitorsMaleMiddle AgedProgrammed Cell Death 1 ReceptorProspective StudiesThyroid GlandAutoantibodiesB7-H1 AntigenCD274 protein, humanImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 Receptorautoimmunitybiomarkerslung neoplasmsprogrammed cell death-1 (PD-1)thyroid

Identifiers

PMID39355355
PMCPMC11439604

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.